What each one is for, how to take it, side effects and warnings, side by side from the official labels.
| Nilotinib | Osimertinib | |
|---|---|---|
| What it is | Kinase Inhibitor | Kinase Inhibitor |
| Used for | Nilotinib capsules are a kinase inhibitor indicated for the treatment of: Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adu… | is a kinase inhibitor indicated for: • adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FD… |
| Usual adult dose | Adult Dose: Newly diagnosed Ph+ CML-CP: 300 mg orally twice daily. | Not on the label |
| Children | Recommended Pediatric Dose: Newly Diagnosed Ph+ CML-CP or Ph+ CML-CP resistant or intolerant to prior TKI therapy: 230 mg/m 2 orally twice daily, rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg). | |
| Prescription (U.S.) | Yes | Yes |
| Common side effects | The following clinically significant adverse reactions can occur with nilotinib and are discussed in greater detail in other sections of labeling: Myelosuppression [ see Warnings and Precautions (5.1) ] QT Prolongation [ see Boxed… | The following adverse reactions are discussed in greater detail in other sections of the labeling: • Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5.1 )] • QTc Interval Prolongation [see Warnings and Precaut… |
| Serious warning | and SUDDEN DEATHS Nilotinib prolongs the QT interval. Prior to nilotinib administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies [ see Warnings and Precauti… | Not on the label |
| Pregnancy | 8.1 Pregnancy Risk Summary Based on findings from animal studies and the mechanism of action, nilotinib can cause fetal harm when administered to a pregnant woman [ see Clinical Pharmacology (12.1) ]… | 8.1 Pregnancy Risk Summary Based on data from animal studies and its mechanism of action [see Clinical Pharmacology (12.1) ] , TAGRISSO can cause fetal harm when administered to a pregnant woman. Ther… |
From the official U.S. labels. Brands and strengths differ between countries.
Neither official label mentions the other. That does not prove they are safe together: ask a pharmacist, and use the free interaction checker.
Check them togetherNilotinib is kinase Inhibitor and Osimertinib is kinase Inhibitor. Nilotinib is used for: Nilotinib capsules are a kinase inhibitor indicated for the treatment of: Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adu… Osimertinib is used for: is a kinase inhibitor indicated for: • adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FD…
Neither official label mentions the other. That does not prove they are safe together: ask a pharmacist, and use the free interaction checker.
It depends on what you are treating, your health and other medicines. Your doctor or pharmacist can tell you which one suits you; this page shows what each official label says.